Nuclear Localization of E-Cadherin Expression in Merkel Cell Carcinoma

2000 ◽  
Vol 124 (8) ◽  
pp. 1147-1151 ◽  
Author(s):  
Aaron C. Han ◽  
Alejandro Peralta Soler ◽  
Chik-Kwun Tang ◽  
Karen A. Knudsen ◽  
Hernando Salazar

Abstract Context.—Cadherins are cell-cell adhesion proteins that act as tumor suppressor genes and have a critical role in cell sorting and tissue formation during organogenesis. The pattern of cadherin expression constitutes a useful diagnostic and prognostic tool in the evaluation of tumors and for determining the histogenesis of tumor cells. We have previously characterized the cell types of several tumors based on the expression of individual cadherins. Objective.—To investigate the expression of cadherins in Merkel cell carcinomas. Design.—Paraffin immunohistochemical analysis of the 3 best-studied cadherins was performed on 35 cases of Merkel cell carcinoma. Results.—E-cadherin was expressed in 34 (97%) of 35 Merkel cell carcinomas examined, N-cadherin was expressed in 22 (63%) of 35 cases, and P-cadherin was expressed in 15 (43%) of 35 cases. This frequency of cadherin expression was similar to a group of small cell and neuroendocrine tumors from other primary sites. Interestingly, the localization of E-cadherin expression was unique in Merkel cell carcinomas compared with other primary neuroendocrine tumors. Merkel cell carcinomas showed marked preference for nuclear versus membrane localization, whereas small cell tumors from other sites showed fewer cases of nuclear E-cadherin expression. The nuclear localization of E-cadherin did not correlate with cadherin-associated protein β-catenin nuclear expression. Conclusions.—Our findings show that E-cadherin is the most frequently expressed cadherin in Merkel cell carcinoma, followed in frequency by N-cadherin then P-cadherin. The pattern of nuclear E-cadherin expression is more frequent for Merkel cell carcinoma than small cell tumors of other primary sites. These observations suggest that E-cadherin expression and function are altered in Merkel cell carcinoma, and this finding has potential use in the differential diagnosis of these tumors.

Cancer ◽  
2001 ◽  
Vol 92 (6) ◽  
pp. 1650-1655 ◽  
Author(s):  
Peter J. Allen ◽  
Klaus Busam ◽  
Arnold D. K. Hill ◽  
Alexander Stojadinovic ◽  
Daniel G. Coit

2001 ◽  
Vol 125 (2) ◽  
pp. 228-231 ◽  
Author(s):  
W. Cheuk ◽  
M. Y. Kwan ◽  
Saul Suster ◽  
John K. C. Chan

Abstract Objective.—To study the expression of thyroid transcription factor 1 (TTF-1) and cytokeratin 20 (CK20) in pulmonary small cell carcinomas, extrapulmonary small cell carcinomas, and Merkel cell carcinomas, and thereby determine whether these markers are helpful in distinguishing these 3 groups of small cell neuroendocrine carcinomas. Materials and Methods.—Immunostaining for TTF-1 and CK20 was performed in 102 cases of small cell carcinoma (pulmonary, 52; extrapulmonary, 50) and 23 cases of Merkel cell carcinoma. The results for the 3 groups were compared. Results.—Thyroid transcription factor 1 was expressed in 82.7% of pulmonary small cell carcinomas, 42.0% of extrapulmonary small cell carcinomas (range, 33.3–53.3% for the various sites), and 0% of Merkel cell carcinomas. Cytokeratin 20 staining was consistently negative in pulmonary small cell carcinomas, and positive in 4.0% of extrapulmonary small cell carcinomas and 100% of Merkel cell carcinomas. Conclusions.—Immunostaining for TTF-1, especially when combined with immunostaining for CK20, can aid in the distinction between Merkel cell carcinoma and small cell carcinoma (both pulmonary and extrapulmonary). However, in individual cases, these markers cannot be used to distinguish between pulmonary and extrapulmonary small cell carcinomas due to the extensive overlap in immunophenotypes.


2012 ◽  
Vol 34 (6) ◽  
pp. 592-596 ◽  
Author(s):  
Charles F. Knapp ◽  
Zena Sayegh ◽  
Michael J. Schell ◽  
Bhupendra Rawal ◽  
Tatiana Ochoa ◽  
...  

2005 ◽  
Vol 46 (6) ◽  
pp. 622-634 ◽  
Author(s):  
B Llombart ◽  
C Monteagudo ◽  
J A Lopez-Guerrero ◽  
C Carda ◽  
E Jorda ◽  
...  

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e15696-e15696
Author(s):  
Aman Chauhan ◽  
Leaundra Murray ◽  
Arun Kumar Arumugam Raajasekar ◽  
Zin Myint ◽  
Lowell Brian Anthony

e15696 Background: Neuroendocrine tumor of unknown primary constitutes about 10-15 % of all neuroendocrine tumors. Identification of primary site can helps alter the management. Sunitinib is FDA approved for management of pancreatic neuroendocrine tumors, everolimus is approved for gastroenteropancreatic and bronchial NETs, immune checkpoint inhibitors are active in Merkel cell carcinoma and MIBG treatment is standard of care for pheochromocytoma. Methods: Patients with neuroendocrine tumor with unknown primary were identified from Markey Cancer Center database over a five-year period (2012-2016). Patient who underwent 92-gene reverse transcriptase polymerase chain reaction cancer classification assay (BioTheranostics Tissue Type ID) were analyzed. IRB approval was obtained. Results: 56 patients with neuroendocrine tumors with unknown primary were identified. Median age of cohort was 61 years. 28/56 patients were males. 92 gene cancer ID assay was used in 38 out of 56 patients. Primary site of tumor was identified with > 95% certainty in 36 out of 38 patients. The test reported pancreatic NET as the primary site for 10 patients, gastrointestinal NETs for 14 patients, bronchial carcinoid for 5, large call NEC for 3, Merkel cell carcinoma for two and pheochromocytoma in one patient. Conclusions: Tissue type ID was able to identify a primary site in NETs of unknown primary in majority (94.7%) of cases. The result had direct implication in management of patients with regards to FDA approved treatment options in 13/38 patients (pNETs, merkel cell and pheochromocytoma).


2013 ◽  
Vol 4 (1) ◽  
pp. 64-71 ◽  
Author(s):  
Ana Maria Abreu Velez ◽  
Billie L. Jackson ◽  
Katya Lisette Velasquez Cantillo ◽  
Andersson Rafael ◽  
Benavides Alvarez ◽  
...  

2012 ◽  
Vol 39 (8) ◽  
pp. 753-757 ◽  
Author(s):  
Rajiv M. Patel ◽  
Laura L. Walters ◽  
Ferdinand Kappes ◽  
Rohit Mehra ◽  
Douglas R. Fullen ◽  
...  

2019 ◽  
Author(s):  
Kashif Rasheed ◽  
Silje Fismen ◽  
Øystein Grimstad ◽  
Baldur Sveinbjørnsson ◽  
Ugo Lionel Moens

Sign in / Sign up

Export Citation Format

Share Document